GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cizzle Biotechnology Holdings PLC (LSE:CIZ) » Definitions » EV-to-FCF

Cizzle Biotechnology Holdings (LSE:CIZ) EV-to-FCF : -9.33 (As of Apr. 04, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Cizzle Biotechnology Holdings EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Cizzle Biotechnology Holdings's Enterprise Value is £5.13 Mil. Cizzle Biotechnology Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2024 was £-0.55 Mil. Therefore, Cizzle Biotechnology Holdings's EV-to-FCF for today is -9.33.

The historical rank and industry rank for Cizzle Biotechnology Holdings's EV-to-FCF or its related term are showing as below:

LSE:CIZ' s EV-to-FCF Range Over the Past 10 Years
Min: -10.41   Med: 0   Max: 0
Current: -10.41

LSE:CIZ's EV-to-FCF is ranked worse than
100% of 440 companies
in the Biotechnology industry
Industry Median: 2.895 vs LSE:CIZ: -10.41

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2025-04-04), Cizzle Biotechnology Holdings's stock price is £0.015. Cizzle Biotechnology Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was £-0.008. Therefore, Cizzle Biotechnology Holdings's PE Ratio (TTM) for today is At Loss.


Cizzle Biotechnology Holdings EV-to-FCF Historical Data

The historical data trend for Cizzle Biotechnology Holdings's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cizzle Biotechnology Holdings EV-to-FCF Chart

Cizzle Biotechnology Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - -5.57 -5.10 -8.67

Cizzle Biotechnology Holdings Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -5.10 - -8.67 -

Competitive Comparison of Cizzle Biotechnology Holdings's EV-to-FCF

For the Biotechnology subindustry, Cizzle Biotechnology Holdings's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cizzle Biotechnology Holdings's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cizzle Biotechnology Holdings's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Cizzle Biotechnology Holdings's EV-to-FCF falls into.


;
;

Cizzle Biotechnology Holdings EV-to-FCF Calculation

Cizzle Biotechnology Holdings's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=5.130/-0.55
=-9.33

Cizzle Biotechnology Holdings's current Enterprise Value is £5.13 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Cizzle Biotechnology Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2024 was £-0.55 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cizzle Biotechnology Holdings  (LSE:CIZ) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Cizzle Biotechnology Holdings's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.015/-0.008
=At Loss

Cizzle Biotechnology Holdings's share price for today is £0.015.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Cizzle Biotechnology Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was £-0.008.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Cizzle Biotechnology Holdings EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Cizzle Biotechnology Holdings's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Cizzle Biotechnology Holdings Business Description

Traded in Other Exchanges
N/A
Address
C/o SGH Secretaries Limited, 60 Gracechurch Street, 6th Floor, London, GBR, EC3V 0HR
Cizzle Biotechnology Holdings PLC is in the early stages of developing a blood test for the early detection of a majority of the different forms of lung cancer. Its proof-of-concept prototype test is based on the ability to detect a stable plasma biomarker, a variant of C1Z1 known as CIZ1B. C1Z1 is a naturally occurring cell nuclear protein involved in DNA replication, and the targeted C1Z1B variant is correlated with early stage lung cancer.

Cizzle Biotechnology Holdings Headlines